Koers Atossa Genetics Inc Nasdaq
Aandelen
US04962H2094
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 192 mln. 179 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -35 mln. -32,67 mln. | Nettowinst (verlies) 2025 * | -39 mln. -36,4 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-5,6
x | K/w-verhouding 2025 * |
-5,16
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,9% |
Recentste transcriptie over Atossa Genetics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 01-12-08 |
Steven Quay
CEO | Chief Executive Officer | 73 | 01-12-08 |
Heather Rees
DFI | Director of Finance/CFO | - | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 01-12-08 |
Director/Board Member | 66 | 01-03-14 | |
H. Remmel
BRD | Director/Board Member | 72 | 01-02-12 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,67% | 42,4 mld. | |
+45,89% | 40,04 mld. | |
-6,20% | 28,31 mld. | |
+6,55% | 24,94 mld. | |
-21,66% | 18,96 mld. | |
+29,96% | 12,3 mld. | |
-1,57% | 11,95 mld. | |
+16,03% | 11,32 mld. | |
-4,80% | 11,55 mld. |